Actively Recruiting

All Genders
ID02897297

Observatory for Philadelphia Negative Myeloproliferative Neoplasms at Brest University Hospital

Led by University Hospital, Brest · Updated on 2024-08-12

1000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This observational study includes patients diagnosed or followed at Brest University Hospital with Philadelphia negative myeloproliferative neoplasms, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The study aims to collect and analyze clinical and biological data from diagnosis through ongoing follow-up to better understand disease progression and outcomes. Clinical information gathered includes patient and disease characteristics at diagnosis, mutational status, cardiovascular risk factors, and history of thrombosis or cancer. Biological data such as hemogram and bone marrow results are recorded when available. During follow-up, treatment changes and their reasons, thrombotic events, phenotypic changes, and deaths with their causes are noted. Participants are observed until the last update, such as death or change of care center. The main outcome measured is overall survival over 10 years, with secondary outcomes including incidence of disease evolutions and thromboses over the same period. Patients who are alive are asked to sign a consent form to continue in the study.

CONDITIONS

Brief Title

Myeloproliferative Neoplastic Diseases Observatory From Brest

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with essential thrombocythemia, polycythemia vera, or primary myelofibrosis
  • Signed non-opposition consent form
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 10 years

Participants who undergo routine care are observed over time with clinical and biological data collected from diagnosis until last news.

Visits as per routine healthcare and follow-up

Trial Site Locations

Total: 1 location

1

CHRU de Brest

Brest, France, 29609

Actively Recruiting

Loading map...

Research Team

J

Jean-Christophe Ianotto

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, ...

Primary Myelofibrosis

Actively Recruiting

1 location

Unmasking Polycythemia Vera in Long-Standing Essential Throm...

Polycythemia Vera

Actively Recruiting

25 locations

A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Admini...

Primary Myelofibrosis

Actively Recruiting

21 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Lise-Marie Mollard, Aurélie Chauveau, Françoise Boyer-Perrard...

https://pubmed.ncbi.nlm.nih.gov/29616837

Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.

Olivier Mansier, Damien Luque Paz, Jean-Christophe Ianotto...

https://pubmed.ncbi.nlm.nih.gov/29266414

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto...

https://pubmed.ncbi.nlm.nih.gov/29246923

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard...

https://pubmed.ncbi.nlm.nih.gov/29217781

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Lenaïg Le Clech, Mehdi Sakka, Ahmed Meskar...

https://pubmed.ncbi.nlm.nih.gov/28482711

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.

Christelle Le Gall-Ianotto, Lanig Civi, Brigitte Pan-Petesch...

https://pubmed.ncbi.nlm.nih.gov/41393215